A Scan May Change Your Plan1,2

Actor portrayals

Imaging with Pixclara® (18F-FET) PET helped guide next steps1,2

In a study of patients with grade 3/4 glioma who had ambiguous MRI results1,2

Patient enrollment1
Patients with grade 3/4 glioma and equivocal MRI after primary treatment (n=42)

18F-FET PET/MRI

Patients diagnosed with progression of disease (POD)1
Following 18F-FET PET/MRI, 30 patients were diagnosed with tumor progression

83%

of patients with POD had patient management changes (25/30)2

Patients diagnosed with treatment-related changes1
Following 18F-FET PET/MRI, 12 patients were diagnosed with treatment-related changes

92%

of patients with treatment-related changes had management maintained (11/12)2

18F-FET PET/MRI accurately confirmed progression of disease in patients with high-grade glioma1

Hybrid 18F-FET PET/MRI performance in these patients demonstrated:

83% specificity and 88% sensitivity

86% accuracy

vs 66% with MRI alone

When used to complement MRI, 18F-FET PET has been shown to improve clinical confidence in glioma management—even in challenging cases1

Study design: A single-center study assessing the clinical application of hybrid 18F-FET PET/MRI to discern POD from treatment-related change in patients with malignant brain tumors and equivocal prior MRI findings, with diagnoses confirmed by pathology or at least 6 months of clinical and imaging follow-up. The study included 42 patients with WHO CNS grade 3 or 4 adult-type diffuse glioma.

See results in pediatric CNS tumors.3

View Results

18F-FET, 18F-fluoro-ethyl-tyrosine; MRI, magnetic resonance imaging; PET, positron emission tomography.